These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26239729)

  • 21. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
    Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
    Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
    Li X; Yu C; Wang T; Chen K; Zhai S; Tang H
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
    Yamada T; Mino Y; Naito T; Kawakami J
    J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
    Owusu Obeng A; Egelund EF; Alsultan A; Peloquin CA; Johnson JA
    Pharmacotherapy; 2014 Jul; 34(7):703-18. PubMed ID: 24510446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms.
    Cendejas-Bueno E; Borobia AM; Gomez-Lopez A; Escosa-García L; Río-García M; Plaza D; García-Rodriguez J; Carcas-Sansuán A
    Int J Antimicrob Agents; 2016 May; 47(5):410-1. PubMed ID: 27056297
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of cyclosporine a and polymorphisms in
    Zeng G; Shi L; Li H; Wang L; Zhu M; Luo J; Zhang Z
    Xenobiotica; 2020 May; 50(5):614-619. PubMed ID: 31573401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
    Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
    Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
    Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
    Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
    Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
    Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
    J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
    Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
    Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations.
    You H; Dong Y; Zou Y; Zhang T; Lei J; Chen L; Wang X; Dong Y; Wang T
    Int J Clin Pharmacol Ther; 2018 May; 56(5):239-246. PubMed ID: 29393850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.
    Calcagno A; Baietto L; Pagani N; Simiele M; Audagnotto S; D'Avolio A; De Rosa FG; Di Perri G; Bonora S
    Pharmacogenomics; 2014 Jul; 15(10):1281-6. PubMed ID: 25155930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
    Zhong X; Tong X; Ju Y; Du X; Li Y
    Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of age and CYP2C19 genotypes on voriconazole steady-state trough concentration in Chinese patients.
    Du YX; Zhu YX; Li L; Yang J; Chen XP
    Pharmacogenet Genomics; 2024 Aug; 34(6):191-198. PubMed ID: 38747453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Voriconazole-refractory invasive aspergillosis.
    Park SY; Yoon JA; Kim SH
    Korean J Intern Med; 2017 Sep; 32(5):805-812. PubMed ID: 28835093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.